Caption Management’s Mereo BioPharma MREO Stock Holding History

Caption Management’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-64,064	Closed	-$21.1K	–	1907
2026 Q1	$21.1K	Buy	64,064 +14,064	+28%	+$6.04K	﹤0.01%	1455
2025 Q4	$20.8K	Sell	50,000 -139,914	-74%	-$266K	﹤0.01%	1491
2025 Q3	$391K	Sell	189,914 -7,685	-4%	-$14.2K	﹤0.01%	1356
2025 Q2	$535K	Buy	197,599 +92,816	+89%	+$224K	0.01%	1098
2025 Q1	$236K	Buy	+104,783	New	+$296K	﹤0.01%	1244

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Caption Management's MREO Position: Q2 2026 in Review

Caption Management sold out of Mereo BioPharma (MREO) in Q2 2026, closing a stake of 64,064 shares — an estimated $21.1K sold.

Caption Management first reported a position in MREO in Q1 2025 and held it in 5 quarters. The position peaked at $535K in Q2 2025. 60 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

Caption Management reported no remaining Mereo BioPharma position as of Q2 2026 after selling out during the quarter.
Caption Management sold 64,064 Mereo BioPharma shares in Q2 2026, an estimated $21.1K.
Caption Management first reported a position in Mereo BioPharma in Q1 2025 and held it in 5 quarters.
Caption Management's Mereo BioPharma position peaked at $535K in Q2 2025.
60 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.